LY4402289
/ Eli Lilly
- LARVOL DELTA
Home
Next
Prev
1 to 1
Of
1
Go to page
1
September 11, 2026
Preclinical characterization of LY4402289, a novel DLL3-targeting antibody drug conjugate (ADC) delivering a NAMPT inhibitor payload
(EORTC-NCI-AACR 2026)
- "Abstract will be available as of 4 November (with consent of the author)"
ADC • Preclinical • Oncology • DLL3 • NAMPT
1 to 1
Of
1
Go to page
1